title: Microcirculation and tolerability following i.v. infusion of PGE1 and iloprost: a randomized cross-over study in patients with critical limb ischemia.
abstract: In a randomized cross-over study, the effect of PGE(1) and iloprost on microcirculation as well as the tolerability was investigated in 36 patients with peripheral arterial occlusive disease stage III and IV according to Fontaine. Patients received PGE(1) and iloprost by single 3-h i.v. infusions on two different days at doses recommended by the manufacturers or in previous studies (PGE(1): first hour 20 microg, next 2h 30 microg each. Iloprost: first hour 0.5 ng/kg/min, next 2h 1.0 ng/kg/min). Transcutaneous oxygen pressure (tcPO(2)) values increased much more with PGE(1). Median tcPO(2) increase over baseline 30 min after the end of infusion was 9 and 2 mmHg for PGE(1) and iloprost, respectively, corresponding to median AUC differences from baseline of 1050 and 210 min mmHg. Because of its exploratory character, the study was not powered to test for significance. Adverse effects occurred in 19.4% (PGE(1)) and 30.6% (iloprost) of patients. Dose reduction was required in 3 patients receiving iloprost (hypotension, nausea, irritation of the infused vein), and in none receiving PGE(1).
authors.affiliation: Department of Angiology, Medical Clinic III, University Clinic Carl Gustav Carus, Fetscherstrasse 74, D-01307 Dresden, Germany. sebastian.schellong@mailbox.tu-dresden.de
authors.forename: S
authors.initials: S
authors.lastname: Schellong
authors.forename: E
authors.initials: E
authors.lastname: Altmann
authors.forename: P
authors.initials: P
authors.lastname: von Bilderling
authors.forename: G
authors.initials: G
authors.lastname: Rudofsky
authors.forename: P
authors.initials: P
authors.lastname: Waldhausen
authors.forename: W
authors.initials: W
authors.lastname: Rogatti
mesh_terms: D000368:Aged; D000369:Aged, 80 and over; D000527:Alprostadil / Q000008:administration & dosage / Q000494:pharmacology* / Q000627:therapeutic use; D018592:Cross-Over Studies; D004361:Drug Tolerance; D005260:Female; D006801:Humans; D016285:Iloprost / Q000008:administration & dosage* / Q000494:pharmacology* / Q000627:therapeutic use; D007262:Infusions, Intravenous; D007511:Ischemia / Q000188:drug therapy* / Q000473:pathology; D007866:Leg / Q000098:blood supply*; D008297:Male; D008833:Microcirculation / Q000187:drug effects*; D014665:Vasodilator Agents / Q000008:administration & dosage / Q000494:pharmacology*
chemical_list: D014665:Vasodilator Agents; D000527:Alprostadil; D016285:Iloprost